SpliceCore Alternatives

Expert-coded by chemists and engineered by computer scientists, SYNTHIA™ Retrosynthesis Software enables scientists to quickly find and easily navigate innovative and novel pathways for novel and published target molecules. Quickly and efficiently scan hundreds of pathways to help you identify the best option according to your needs. Explore the most cost-effective routes to your target molecules with state of the art visualization and filtering options. Easily customize search parameters to eliminate or promote reactions, reagents or classes of molecules. Explore unique and innovative syntheses that may be unknown for building your desired molecule. Easily generate a list of commercially available starting materials for your synthesis. Benefit from ISO/IEC 27001 Information Security Certification to guarantee the confidentiality, integrity, and protection of your data.

We use our AI engine to transform drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio includes wholly-owned and co-developed pipeline assets, and is backed by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. The secret to reinventing drug discovery with AI is people. We are dedicated to developing the best AI platform and using it to transform small molecule drug discovery. We have to tackle the most challenging, seemingly impossible targets and streamline the drug discovery process to give drug developers more shots on goal. Computational efficiency enables screening of trillions of compounds in silico, increasing the likelihood of success. Demonstrated exquisite model accuracy, overcoming the challenge of false positives.

We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering to industrialize drug discovery. Increased control over biology with tools such as CRISPR genome editing and synthetic biology. Reliable automation of complex laboratory research at an unprecedented scale using advanced robotics. Iterative analysis of, and inference from, large, complex in-house datasets using neural network architectures. Increasing elasticity of high-performance computation using cloud solutions. We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. A synchronized combination of hardware, software and data used to industrialize drug discovery. Reshaping the traditional drug discovery funnel. One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company.

BIOiSIMTM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. We offer a range of translational-based solutions, customized for your pre-clinical and clinical programs. These offerings are all centered around our proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses. Our models are built on data from thousands of compounds across 7 species, leading to robustness rarely seen in the industry. With a focus on human outcomes, the platform has at its core a translatability engine that transforms insights across species. The BIOiSIMTM platform can be used before the preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.

BioNeMo is an AI-powered drug discovery cloud service and framework built on NVIDIA NeMo Megatron for training and deploying large biomolecular transformer AI models at a supercomputing scale. The service includes pre-trained large language models (LLMs) and native support for common file formats for proteins, DNA, RNA, and chemistry, providing data loaders for SMILES for molecular structures and FASTA for amino acid and nucleotide sequences. The BioNeMo framework will also be available for download for running on your own infrastructure. ESM-1, based on Meta AI’s state-of-the-art ESM-1b, and ProtT5 are transformer-based protein language models that can be used to generate learned embeddings for tasks like protein structure and property prediction. OpenFold, a deep learning model for 3D structure prediction of novel protein sequences, will be available in BioNeMo service.

Clara’s domain-specific tools, AI pre-trained models, and accelerated applications are enabling AI breakthroughs in numerous fields, including medical devices, imaging, drug discovery, and genomics. Explore the end-to-end pipeline of medical device development and deployment with the Holoscan platform. Build containerized AI apps with the Holoscan SDK and MONAI, and streamline deployment in next-generation AI devices with the NVIDIA IGX developer kits. The NVIDIA Holoscan SDK includes healthcare-specific acceleration libraries, pre-trained AI models, and reference applications for computational medical devices.

InSilicoTrials.com is a web-based platform, which provides a user-friendly computational modeling and simulation environment where many integrated easy-to-use in silico tools are readily available. The platform targets primarily users from the medical devices and pharmaceutical sectors. The in silico tools available for medical devices enable computational testing in different biomedical areas like radiology, orthopedics and cardiovascular during product design, development and validation processes. For the pharmaceutical sector, the platform provides access to in silico tools developed at all stages of the drug discovery and development processes and for many different therapeutic areas. We have built the only cloud-platform based on the crowdscience concept that makes it easy to use validated models and cut your R&D costs now. A growing catalogue of models ready to be used, on a pay per use basis.

Genedata Biologics® streamlines discovery of biotherapeutics including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs. The most widely adopted platform across the industry, it integrates all discovery workflows so you can focus on true innovation. Accelerate research with a first-in-class platform uniquely designed from the start to digitalize biotherapeutic discovery. The platform facilitates complex R&D processes by designing, tracking, testing, and assessing novel biotherapeutics drugs. It works with any format, from antibodies, bi- or multi-specifics, ADCs, novel scaffolds, and therapeutic proteins, to engineered therapeutic cell lines such as TCRs and CAR-T cells. Acting as a central end-to-end data backbone, Genedata Biologics integrates all R&D processes, from library design and immunizations, selections and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, to candidate developability and manufacturability assessments.

LiveDesign is an enterprise informatics platform that enables teams to rapidly advance drug discovery projects by collaborating, designing, experimenting, analyzing, tracking, and reporting in a centralized platform. Capture ideas alongside experimental and modeling data. Create and store new virtual compounds in a centralized database, evaluate through advanced models, and prioritize new designs. Integrate biological data and model results across federated corporate databases, apply sophisticated cheminformatics to analyze all data at once, and progress compounds faster. Drive predictions and designs using advanced physics-based methods paired with machine learning techniques to rapidly improve prediction accuracy. Work together with remote team members in real-time. Share ideas, test, revise, and advance chemical series without losing track of your work.

Transform drug discovery and materials research with advanced molecular modeling. Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space. Our platform is deployed by industry leaders worldwide for drug discovery, as well as for materials science in fields as diverse as aerospace, energy, semiconductors, and electronics displays. The platform powers our own drug discovery efforts, from target identification to hit discovery to lead optimization. It also drives our research collaborations to develop novel medicines for critical public health needs. With more than 150 Ph.D. scientists on our team, we invest heavily in R&D. We’ve published over 400 peer-reviewed papers that demonstrate the strength of our physics-based approaches, and we’re continually pushing the limits of computer modeling.

With its comprehensive suite of integrated software, StarDrop™ delivers best-in-class in silico technologies within a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through predictive modeling to decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. Successful compounds require a balance of many different properties. StarDrop™ guides you through this multi-parameter optimization challenge to target compounds with the best chance of success, saving you time and resources by enabling you to synthesize and test fewer compounds.

Bringing a new drug into the market, from the first step to the final market introduction, is a time-consuming, highly regulated, and expensive process, which can take a decade or more. Final success crucially depends on the early availability of accurate analytical results, fast enough for taking the right decisions at the beginning of the development and minimizing late attrition rates. Today’s drug development is mainly based on a rational approach where typically establishing the biological target to focus on is the first key step. This target identification requires a deep understanding of the candidates´ properties to identify the most promising ones as quickly and reliable as possible. Once a biological target has been established, finding the most promising lead molecules is often seen as the next challenge. Typically, lead discovery is the identification of potential drug candidates – either small organic molecules or biologic assemblies with therapeutic potential.

Eidogen-Sertanty's Target Informatics Platform (TIP) is the world's first structural informatics system and knowledgebase that enables researchers with the ability to interrogate the druggable genome from a structural perspective. TIP amplifies the rapidly expanding body of experimental protein structure information and transforms structure-based drug discovery from a low-throughput, data-scarce discipline into a high-throughput, data-rich science. Designed to help bridge the knowledge gap between bioinformatics and cheminformatics, TIP supplies drug discovery researchers with a knowledge base of information that is both distinct from and highly complementary to information furnished by existing bio- and cheminformatics platforms. TIP's seamless integration of structural data management technology with unique target-to-lead calculation and analysis capabilities enhances all stages of the discovery pipeline.

Scitara DLX™ offers a rapid connectivity infrastructure for any instrument in the life science laboratory in a fully compliant and auditable cloud-based platform. Scitara DLX™ is a universal digital data infrastructure that connects any instrument, resource, app and software in the laboratory. The cloud-based, fully auditable platform connects all data sources across the lab, allowing the free flow of data across multiple end points. This allows scientists to devote their time to scientific research, not waste it solving data issues. DLX curates and corrects data in flight to support the development of accurate, properly structured data models that feed AI and ML systems. This supports a successful digital transformation strategy in the pharma and biopharma industries. Unlocking insights from scientific data enables faster decision-making in drug discovery and development, helping bring drugs to market more quickly.

AIDDISON™ drug discovery software combines the power of artificial intelligence (AI), machine learning (ML), and 3D computer-aided drug design (CADD) methods to act as a valuable toolkit for medicinal chemistry needs. As a unified platform for efficient and effective ligand-based and structure-based drug design, it integrates all the facets for virtual screening and supports methods for in-silico lead discovery and lead optimization.

Leverage the power of AI to expedite the journey from bench research and laboratory insights to the launch of life-changing therapies. Gain up to 90% in research productivity by reducing your reading time from months to minutes. Cut through the noise with a high-precision, high-accuracy search to navigate the ever-growing volume of scientific literature with ease. Save time, reduce bias and increase odds of novel discoveries. Deeply explore disease biology and conduct advanced target discovery. Causaly’s high-precision knowledge graph consolidates evidence from millions of publications, making deep, unbiased scientific exploration possible. Rapidly navigate biological cause-and-effect relationships without being an expert. Get a view of all scientific documents and uncover hidden connections. Causaly’s powerful AI machine reads millions of published biomedical literature to support better decision-making and research outcomes.

Kanteron Platform ingested medical images, digital pathology slides, genomics sequences, and patient data from modalities, scanners, sequencers and databases, and provided a complete data toolkit to every team in hospital networks. Pharmacogenomics for adverse medication event prevention, and Precision Medicine application at the point of care: Incorporates sources of drug-gene interaction data that were previously only available in in accessible formats (e.g. tables in a PDF document), implementing the major Pharmacogenomic databases (like PharmGKB, CGI, DGIdb, OpenTargets...) Allows the user to refine their query to certain gene families, types of interactions, classes of drugs, etc. Flexible AI means you can choose the data set that best fits your use case, and apply it to your relevant medical images.

Pharma companies need comprehensive genomic information to drive successful precision medicine programs, but decisions are often made using only a fraction of the data available, about 10%. Genomenon delivers 100% of the data. An efficient and cost-effective natural history research solution for pharma, ProdigyTM Patient Landscapes support the development of rare disease therapies by enhancing insights contained in retrospective and prospective health data. Using a powerful AI-driven approach, Genomenon delivers a comprehensive and expert assessment of every patient in the published medical literature, in a fraction of the time. Don’t miss anything, get insight into every genomic biomarker published in the medical literature. Every scientific assertion is supported by empirical evidence from the medical literature. Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards.

Mantarray brings functional data into the earliest stages of preclinical testing of new medicines. By providing parallel analysis of 3D engineered muscle tissues with adult-like functional profiles, Mantarray enables the discovery, safety, and efficacy testing of new therapeutics. With over 95% tissue formation success rate, the Mantarray Plate Kit allows for reliable and reproducible engineered tissues across 24 wells. The Mantarray platform provides an easy-to-use, scalable, and flexible system that allows researchers to examine 3D tissues in vitro in the convenience of their own lab. Be among the first to receive the instrument. The Mantarray system features a novel magnetic sensing technique that can detect the contraction of EMTs. This enables the user to measure the contractility of 24 tissues in parallel, a high throughput, and in real time. The system features user-friendly software that takes away the requirement for manual calculations of contractility.

Proven AI-powered drug discovery. Cerella creates new value from your drug discovery data, revealing hidden insights into the best compounds and most valuable experiments for your project. It makes confident predictions, accurately filling in missing values, especially for expensive downstream experiments that can’t be predicted by other methods. This enables you to do more, even with sparse, limited data sets.

Rare diseases are often not well studied and there is a limited understanding of many of the aspects necessary to support a drug discovery program. Our AI platform, Healnet, overcomes these challenges by analyzing millions of drug and disease data points to find novel connections that could be turned into new treatment opportunities. By applying frontier technologies across the discovery and development pipeline, we can run multiple stages in parallel and at scale. One disease, one target, one drug: it's an overly simple model, yet it's the one used by nearly all pharmaceutical companies. The next generation of drug discovery is AI-powered, parallel and hypothesis-free. Bringing together the key three drug discovery paradigms.

Today’s biopharmaceutical industry is marked by complexity: growing market demands for improved specificity and safety, novel treatment classes and more intricate mechanisms of disease. Keeping up with this complexity requires a deeper understanding of therapeutic behavior. Modeling and simulation methods provide a unique means to explore biological and physicochemical processes down to the atomic level. This can guide physical experimentation, accelerating the discovery and development process. BIOVIA Discovery Studio brings together over 30 years of peer-reviewed research and world-class in silico techniques such as molecular mechanics, free energy calculations, biotherapeutics developability and more into a common environment. It provides researchers with a complete toolset to explore the nuances of protein chemistry and catalyze discovery of small and large molecule therapeutics from Target ID to Lead Optimization.

Amazon Neptune is a fast, reliable, fully managed graph database service that makes it easy to build and run applications that work with highly connected datasets. The core of Amazon Neptune is a purpose-built, high-performance graph database engine optimized for storing billions of relationships and querying the graph with milliseconds latency. Amazon Neptune supports popular graph models Property Graph and W3C's RDF, and their respective query languages Apache TinkerPop Gremlin and SPARQL, allowing you to easily build queries that efficiently navigate highly connected datasets. Neptune powers graph use cases such as recommendation engines, fraud detection, knowledge graphs, drug discovery, and network security. Proactively detect and investigate IT infrastructure using a layered security approach. Visualize all infrastructure to plan, predict and mitigate risk. Build graph queries for near-real-time identity fraud pattern detection in financial and purchase transactions.

Altis Labs announces launch of Nota – a clinical information platform to accelerate therapeutic R&D Nota leverages. AI to predict patient outcomes from imaging data so sponsors can better prioritize their most promising therapies. Nota enables researchers to operationalize clinical trial imaging data, access predictive imaging biomarkers, and accelerate R&D at scale. Using Altis’ cloud-based software platform powered by deep learning, biopharma can incorporate comprehensive outcome predictions at the image, patient, and cohort level to improve clinical trial design and more confidently anticipate clinical endpoints. Such insights have the potential to significantly accelerate development timelines, lower drug development costs, and improve the likelihood of trial success across therapeutic areas.

BC platforms leverages latest science, unique technology capabilities, and strategic partnerships to achieve our mission of revolutionizing drug discovery and personalizing care. Modular, highly configurable platform for integrated healthcare data. Open analytics framework seamlessly combining latest innovative methods, analytics and technology developments in one single platform. Superior security: ISO 27001 certified, GDPR and HIPAA compliance. Complete product portfolio enabling a modern healthcare system to fully embrace personalized medicine. Scalable deployments enabling a robust start as well as large scale healthcare operation. Accelerated translation of research insights into clinical practice with our unique end to end toolbox. We help reduce your risk, enhance your pipeline value and advance your enterprise data strategy by solving the barriers of data access and enabling rapid insight generation.

VeraChem LLC was founded in 2000 to advance the state of the art in computer-aided drug discovery and molecular design by developing computational chemistry methods that are based on cutting-edge basic science but are also applicable in applied science research settings. Efficient high-performance software implementations of these methods coupled with comprehensive user support are a central company strategy for product development. Current VeraChem software capabilities include protein-ligand and host-guest binding affinity prediction, fast calculation of accurate partial atomic charges for drug-like compounds, computation of energies and forces with all the commonly used empirical force fields, automatic generation of alternate resonance forms of drug-like compounds, conformational search with the powerful Tork algorithm, and automatic detection of topological and 3D molecular symmetries. VeraChem’s software packages are constructed from a modular code base.

DNAnexus Apollo™ accelerates precision drug discovery by unlocking the power of collaboration to draw critical insights from omics data. Precision drug discovery requires collecting and analyzing huge volumes of omics and clinical data. These datasets are incredibly rich resources, but most legacy and home-grown informatics tools can't cope with their size and complexity. Precision medicine programs can also be hampered by siloed data sources, underpowered collaboration tools, and the burden of complex and always changing regulatory and security requirements. DNAnexus Apollo™ supports precision drug discovery programs by empowering scientists and clinicians to explore and analyze omics and clinical data together, in a single environment, built on a robust, scalable cloud platform. Apollo lets them share data, tools, and analyses easily and securely with peers and collaborators everywhere - whether they're on another floor, or another continent.

NVIDIA® Parabricks® is the only GPU-accelerated suite of genomic analysis applications that delivers fast and accurate analysis of genomes and exomes for sequencing centers, clinical teams, genomics researchers, and high-throughput sequencing instrument developers. NVIDIA Parabricks provides GPU-accelerated versions of tools used every day by computational biologists and bioinformaticians—enabling significantly faster runtimes, workflow scalability, and lower compute costs. From FastQ to Variant Call Format (VCF), NVIDIA Parabricks accelerates runtimes across a series of hardware configurations with NVIDIA A100 Tensor Core GPUs. Genomic researchers can experience acceleration across every step of their analysis workflows, from alignment to sorting to variant calling. When more GPUs are used, a near-linear scaling in compute time is observed compared to CPU-only systems, allowing up to 107X acceleration.

Makya is the first user-friendly SaaS platform for AI-driven de novo drug design focused on Multi-Parametric Optimization (MPO). It enables the design of novel and easy-to-make compounds in line with a multi-objective blueprint with unprecedented speed, performance, and diversity. Makya offers multiple generative algorithms covering different use cases from hit discovery to lead optimization: fine-tuning generator to find optimal solutions within your chemical space in line with your project blueprint; novelty generator to find new ideas with high novelty for re-scaffolding/hit discovery; forward generator to design a focused library of compounds easily accessible from commercial starting materials. The new Makya 3D module enhances the user experience and scientific utility of Makya. With an extensive set of 3D modeling features in both ligand-based and structure-based pipelines, with Makya 3D you can now calculate 3D scores and use these to guide generations natively in Makya.

We integrate clinical and experimental data using machine learning to navigate human disease biology and advance precision medicines. Our patent-pending Contingent AI™ understands relationships within the data to provide sophisticated insights. We address data bias by iterating on machine learning models based upon decisions made in the pre-processing and feature engineering stages. We leverage zebrafish, cellular and other phenotypic animal models to validate in silico predictions in vivo experiments and genetically modify them in vitro and in vivo, to improve translation. Using active learning and computer vision on validated models for cardiac, central nervous system and rare disorders, we rapidly incorporate new data into our machine learning models.

AutoDock is a suite of automated docking tools. It is designed to predict how small molecules, such as substrates or drug candidates, bind to a receptor of known 3D structure. Over the years, it has been modified and improved to add new functionalities, and multiple engines have been developed. Current distributions of AutoDock consist of two generations of software: AutoDock 4 and AutoDock Vina. More recently, we developed AutoDock-GPU, an accelerated version of AutoDock4 that is hundreds of times faster than the original single-CPU docking code. AutoDock 4 actually consists of two main programs: autodock performs the docking of the ligand to a set of grids describing the target protein; autogrid pre-calculates these grids. In addition to using them for docking, the atomic affinity grids can be visualized. This can help, for example, to guide organic synthetic chemists design better binders.

The microbiome is implicated in numerous diseases and health conditions. Learn how Kaleido is leading a differentiated approach to translating the promise of the microbiome into solutions for patients. The human microbiome is a community of more than 30 trillion microbes, organisms that include bacteria, viruses, archaea and fungi, which reside on and inside the human body. Over the last decade, research has increased exponentially on the impact the microbiome has on human health, including cardiovascular disease, cancer, diabetes, Parkinson’s disease and allergies. This highly complex microbial ecosystem has been referred to as a “newly discovered organ.” Many other human organs command tens of billions of dollars for therapeutics that treat disease by modulating physiology. From a therapeutic perspective, the microbiome organ remains a largely untapped frontier in healthcare.

Discover biological biomarkers, create insights into disease mechanisms, discover new drugs or identify changes in protein levels from a set of carefully designed experiments. We’ve made it easy to start unlocking the power of MS and Proteomics so you can focus on the biological complexity and move closer to the moment of discovery. Our automated and repeatable workflow allows for quicker experiment startup and turnaround times, giving you the control and flexibility to make and act on decisions in the moment. Allowing you to focus on biological insights and human-to-human collaboration, our proteomics data processing workflow is built to scale, repeatedly. We’ve pushed heavy and repetitive processing to the cloud, enabling a seamless and enjoyable experience. Our intelligent Proteomics workflow seamlessly integrates complex moving parts to enable larger experiments to be processed and analyzed with ease.

NoviSight 3D cell analysis software advances your discovery by providing statistical data for spheroids and other 3D objects in microplate-based experiments. The software enables you to quantify cell activity in three dimensions and more easily capture rare cell events, obtain accurate cell counts, and improve detection sensitivity. With a convenient user interface, NoviSight software offers the tools you need for recognition, analysis, and statistics. NoviSight software’s True 3D technology makes it easier to check the morphology of your samples. Measure a range of spheroid or cell nuclei parameters, including volume and sphericity, and measure and analyze physiologically relevant 3D cell models to speed up your research work. The software can analyze objects of interest to provide morphology and spatiotemporal parameters in 3D space. Detect objects from whole structures to subcellular features and evaluate changes in spheroids.

Deliver personalized patient care with the only histologically validated, objective, and quantitative CTA-based arterial analysis software. Utilize ground-truth histology to visualize the source of myocardial ischemia and inform heart attack and stroke risk. Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated. Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops. Elucid is harnessing scientific imaging and artificial intelligence to enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes. Assess plaque composition with histology-validated software. Quantify heart attack and stroke risk with greater accuracy. Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital.

Healthcare professionals & pharmaceutical companies use RetinAI's software platform discovery to manage their data, gain enhanced insights with automatic AI analysis, and supercharge clinical and research workflows. A single data platform to manage & access your data anytime from anywhere. Compatible formats include DICOM-compliant and proprietary formats. Data is harmonized, organized, aggregated & analyzed at scale using AI to extract insights about disease progression, treatment outcomes & progression prediction. Enable participative research across your organization with secured cloud-based access to data. The town square for data, medical, and digital teams. Perform AI-based analysis on your OCT volumes for layer & fluid segmentation. Provide immediate evaluation & centralize your insights in a single platform. Instantly invite collaborators to access and work with datasets with different permission levels.

EVIDENS, our AI platform enables digital cohort discovery, research, collaboration, and insight sharing on hospital-wide data sets. Quickly annotate and link your data into AI-ready data sets. Quickly filter populations based on clinical outcomes or demographics. Filter populations with limitless keywords by training AI models to search with them. Explore and create criteria to identify cohorts with smart AI assistance. Quickly train AI models to automate analysis and categorize data into groups. Output AI-ready cohorts to test your study’s clinical hypothesis. Easily view the status and tasks for all your projects and collaborators. View and follow activity based on your research interests and projects. Use collaborative tools to work in parallel to create, train and validate AI models.

Splice Machine is a scalable SQL database that enables companies to modernize their legacy and custom applications to be agile, data-rich, and intelligent – all without re-writes.

We are an artificial intelligence-enabled SaaS that diagnoses drug-resistant tuberculosis in a few hours. AarogyaAI aims to diagnose drug-resistant tuberculosis (DR-TB) using Artificial Intelligence in a few hours. We enable quick and accurate diagnosis of DR-TB so that the patient can be rightly prescribed effective drug combinations for treatment, instantly. Tuberculosis claims more lives every year than AIDS. This is because, of the 19 anti-TB drugs available, doctors don’t always know which ones will work for whom. Thus, even though tuberculosis is curable, a delayed diagnosis of drug-resistant tuberculosis can mean patients are on ineffective medication for up to 7 years. AarogyaAI aims to diagnose drug-resistant tuberculosis in a few hours so that a patient can be prescribed effective treatment, instantly. We use a DNA sequence from the patient which is uploaded to our SaaS. Our machine learning algorithm then gives an output report of a comprehensive drug susceptibility status.

Our reputation as thought leaders in the areas of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology is earned through the success our clients have found through their relationship with us. We have the talent and 20+ years of experience to translate science into user-friendly software and provide expert consulting supporting drug discovery, clinical development research, and regulatory submissions.

With CDD Vault, you can intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Start your free trial and see first hand how easy it is to manage drug discovery data. Tailored for you Affordable Scales with your project team(s) Activity & Registration * Electronic Lab Notebook (ELN) * Visualization * Inventory * APIs * Secure Online Hosting

Automated surveillance of any data source, fully integrated with a GVP IX compliant signal management platform. GVP-IX compliant signal management platform integrated within Evidex and ready to use off-the-shelf. Modernize and audit-proof your management processes without having to move back and forth between platforms and services. Unlock the value of your safety data. When you automate signal detection and management, you can focus not just on regulatory requirements, but on driving value for your organization. Identify safety signals from traditional sources like ICSR databases, FDA Adverse Event Reporting System (FAERS), VigiBase and clinical trial data. Include new data sources such as claims, EHR, and other unstructured data. Bring these pools of information together seamlessly to enhance signaling algorithms, make validations and assessment more efficient, and provide faster answers to drug safety questions.

ArgusLab is a molecular modeling, graphics, and drug design program for Windows operating systems. It’s getting a little dated by now, but remains surprisingly popular. To date, there are more than 20,000 downloads. ArgusLab is freely licensed. You don’t need to sign anything. You can use as many copies as you need if you are teaching a class where your students might benefit from using ArgusLab. You are not allowed to redistribute ArgusLab from other websites or sources. However, you may link to this website from your own websites if you like. A low-key effort is currently underway to port ArgusLab to the iPad. In addition, I’ve done some work with the Qt cross-platform development environment in an effort to support Mac, PC, and Linux.

To accelerate new discoveries and get products to market as quickly as possible, R&D and manufacturing labs have to reconfigure and change on the fly. Data management can’t be a bottleneck. Developed in partnership with customers in fast-paced R&D environments, the Thermo Scientific™ Nautilus LIMS™ for Dynamic Discovery and R&D Environments is a highly flexible, easily configurable system that increases workflow efficiency, throughput and data reliability while simplifying administration, sample traceability and regulatory compliance. Automated handling of complex boards and proprietary graphics instruments make data monitoring and management easy, even novice users can delineate and track processes with ease. Clients can create workflows, delineate the life cycles of the samples and automate actions between different platforms while integrating regulated processes that comply with good laboratory practices and the 21 CFR Part 11 guidelines.

In many laboratories, preclinical information resides in numerous internal systems and among several external partners. Without a unified solution, team members lack the necessary transparency of core business data to enable clear and informative decisions. Pristima is a fully integrated digital laboratory execution system with intelligent workflows, task automation, connected systems and facilities, and data and information management for the entire preclinical process. With a central data repository and standardized archive platform, Xybion has created a total preclinical solution platform to help you improve productivity and reduce costs. Gain visibility into information where it resides and initiate actions based on current business requirements with complete transparency across all platforms. Decrease end-of-study to final SEND submission timelines with effective data management.

Our regulatory compliant platform empowers clinical research by algorithmically analyzing unstructured EMR data for life endangering conditions. We build technologies that expand access to the most Innovative Healthcare through Clinical Trials. We are a team focused on saving lives by providing access to healthcare therapeutic innovations that are still under investigation. We believe that every patient should be empowered and educated on their opportunities to participate in clinical trials that may offer therapies significantly saving or improving their lives. We are an advanced healthcare AI research company that have developed a computational-based platform to identify patients who match a complex set of criteria to participate in clinical trials.

Making health data more accessible for better decisions at lower costs. Binah.ai’s health data platform is an AI-powered, video-based, software-only solution that allows any industry in need of real-time health data to easily extract a wide range of end-user-provided health parameters in a simple, easily accessible and digital format. Health parameters include heart rate, heart rate variability (HRV SDNN and RRI raw data), oxygen saturation, respiration rate, sympathetic stress, parasympathetic activity, pulse-respiration quotient (PRQ) and soon, blood pressure. Removing the need for wearables or other dedicated hardware, Binah.ai’s health data platform, available as a software development kit (SDK), supports a wide range of devices and operating systems to enable seamless health and wellness monitoring using a personal electronic device that end-users already possess, a smartphone, tablet or laptop.

Our industry-leading, artificial intelligence (AI)–driven technology converts both structured and unstructured healthcare data into a high-quality, reliable, standardized dataset that can be used across your organization. Accessing data in near real-time from disparate systems, our products and services reduce the burden of manual data abstraction so your administrative and clinical teams can recapture that time for quality and research initiatives. Our products and services allow you to collect, analyze, and act on your data, regardless of data source, therapeutic area, organizational department, or existing reporting, BI, or analytics tools. Atlas uses human expertise and the power of AI to automate and simplify the resource-consuming task of finding and interpreting patient data for clinical registries. Cartographer searches, analyzes, and interprets patient data across all platforms, standardizes those data into a consistent format, and provides relevant data recommendations.

By detecting early-stage cancers, AI enables timely management that can increase the chance of survival through AI. Cancer is complex. Every cancer is unique in its own way, containing vast information that needs to be processed. Complex is what AI does best. With its analysis that extends human capacity, AI can unlock cancer information that leads us to new revelations that can serve as a key strategy in fighting cancer. Armed with the accurate and appropriate information, we can take a step ahead in the war on cancer. Through AI, we can conquer cancer. We develop AI that detects early-stage cancer and optimizes cancer treatment. Detects with 97-99% accuracy. Accurately detects 10 of the most common findings in a chest x-ray. Improving the most basic and universal diagnostic test. Alleviating the burden in radiology workflow. Lunit INSIGHT CXR covers the vast majority of findings. Accurately detects 10 of the most common findings in a chest x-ray.

BeeKeeperAI™ uses privacy-preserving analytics on multi-institutional sources of protected data in a confidential computing environment including end-to-end encryption, secure computing enclaves, and Intel’s latest SGX enabled processors to comprehensively protect the data and the algorithm IP. The data never leaves the organization’s protected cloud storage, eliminating the loss of control and “resharing” risk. Uses primary data - from the original source - rather than synthetic or de-identified data. The data is always encrypted. Healthcare-specific powerful BeeKeeperAI™ tools and workflows support data set creation, labeling, segmentation, and annotation activities. The BeeKeeperAI™ secure enclaves eliminate the risk of data exfiltration and interrogation of the algorithm IP from insiders and third parties. BeeKeeperAI™ acts as the middleman & matchmaker between data stewards and algorithm developers, reducing time, effort, and costs of data projects by over 50%.